Hyaluronic acid as a marker for remodeling of bronchopulmonary system in patients with occupational pulmonary pathology

Currently there is no convincing evidence concerning pathogenetic mechanisms of fibrous and sclerotic processes in pulmonary tissue as well as processes of bronchopulmonary system remodeling in patients with chronic obstructive pulmonary disease (COPD) of occupation etiology (OE).

The purpose of the study was to identify relationship between the serum hyaluronic acid (HA) level and severity of obstructive pulmonary ventilation impairment according to spirometry data in subjects with COPD associated with the impact of silica-containing dust and chronic occupational non-obstructive (common) bronchitis (CONB) of occupational etiology.

Materials and Methods. Patients (n = 153) with the diagnosis OE COPD (n = 92), OE CONB (n = 36) and healthy subjects participated in the study.

Results. The study data demonstrated that serum HA level in patients with OE COPD and CONB was 3–5 times higher than that in healthy subjects (p = 0.0001). In patients with OE COPD HA concentration was significantly higher, than that in subjects with OE CONB (p = 0.039). Negative correlation between HA concentration and forced expiratory volume in 1 second value was observed (p = 0.006; R = –0.31). There was statistically significant positive correlation between HA level and disease duration (р = 0.021; R = 0.21).

Conclusion. Serum HA level in patients with OE-related COPD and CONB may be used as a biomarker of fibrous and sclerotic process in pulmonary tissue, reflecting progression of obstruction and remodeling of small bronchi.

1. Shmelev E.I. [Anti-inflammatory therapy with fenspiride in patients with chronic obstructive pulmonary disease]. Consilium Medicum. 2008; (pril.): 35–39 (in Russian).

2. Shaw J.G., Vaughan А., Dent A.G. et al. Biomarkers of progression of chronic obstructive pulmonary disease (COPD). J. Thorac. Dis. 2014; 6 (11): 1532–1547. DOI: 10.3978/j.issn.2072-1439.2014.11.33.

3. Caramori G., Adcock I., Di Stefano A., Chung K.F. Cytokine inhibition in the treatment of COPD. Int. J. COPD. 2014; 9 (1): 397–412. DOI: 10.2147/COPD.S42544.

4. Garantziotis S., Brezina M., Castelnuovo P., Drago L. The role of hyaluronan in the pathobiology and treatment of respiratory disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 2016; 310 (9): L785–795. DOI: 10.1152/ajplung.00168.2015.

5. Wilkinson T.S., Potter-Perigo S., Tsoi C. et al. Pro- and anti-inflammatory factors cooperate to control hyaluronan synthesis in lung fibroblasts. Am. J. Respir. Cell. Mol. Biol. 2004; 31 (1): 92–99. DOI: 10.1165/rcmb.2003-0380OC.

6. Lennon F.E., Singleton P.A. Role of hyaluronan and hyaluronan-binding proteins in lung pathobiology. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2011; 301 (2): L137–147. DOI: 10.1152/ajplung.00071.2010.

7. Ormiston M.L., Slaughter G.R.D., Deng Y. et al. The enzymatic degradation of hyaluronan is associated with disease progression in experimental pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010; 298 (2): L148–157. DOI: 10.1152/ajplung.00097.2009.

8. Dentener M.A., Vernooy J.H., Hendriks S., Wouters E.F. Enhanced levels of hyaluronan in lungs of patients with COPD: relationship with lung function and local inflammation. Thorax. 2005; 60 (2): 114–119. DOI: 10.1136/thx.2003.020842.

9. Eurlings I.M., Dentener M.A., Mercken E.M. et al. A comparative study of matrix remodeling in chronic models for COPD; mechanistic insights into the role of TNF-α. Am. J. Physiol. Lung Cell. Mol. Physiol. 2014; 307 (7): L557–565. DOI: 10.1152/ajplung.00116.2014.

10. Tuder R.M., Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J. Clin. Invest. 2012; 122 (8): 2749–2755. DOI: 10.1172/JCI60324.

11. Rodríguez E., Ferrer J., Zock J.P. et al. Lifetime occupational exposure to dusts, gases and fumes is associated with bronchitis symptoms and higher diffusion capacity in COPD patients. PLoS One. 2014; 9 (2): e88426. DOI: 10.1371/journal.pone.0088426.

12. Izmerov N.F., Chuchalin A.G., ed. [Occupational respiratory diseases: National Guidance]. Moscow: GEOTAR-Media; 2015 (in Russian).

13. Aisanov Z.R., Avdeev S.N., Arkhipov V.V.et al. [National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary disease: a clinical decisionmaking algorithm]. Pul'monologiya. 2017; 27 (1): 13–20 DOI: 10.18093/0869-0189-2017-27-1-13-20 (in Russian).

14. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2017 GOLD Report. Доступно на: https://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/ [Дата обращения 10.06.2018].

15. Organov R.G., Mamedov M.N., eds. [National clinical guidelines. Version 3]. Moscow: Solitseya-Poligra; 2010 (in Russian).

16. Papakonstantinou E., Roth M., Klagas I. et al. COPD exacerbations are associated with proinflammatory degradation of hyaluronic acid. Chest. 2015; 148 (6): 1497–1507. DOI: 10.1378/chest.15-0153.

17.